BioSpace News Archive

Assertio Holdings, Inc. announced that it is raising its outlook for 2022 full-year net product sales to greater than $152 million, increased from its prior outlook calling for net product sales of greater than $141 million for the full year.

Harpoon Therapeutics, Inc. today announced that it will host a conference call and webcast to review updated interim results of its Phase 1 HPN217 clinical program presented at the 64th American Society of Hematology (ASH) Annual Meeting and provide a corporate update.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, on December 2, 2022 filed with the SEC its financial results and related management’s discussion for the third quarter ended September 30, 2022.

Arthrex, a global leader in minimally invasive orthopedic technology, has launched the award-winning Arthrex Minimally Invasive Bunionectomy System to offer patients a better solution to traditional bunion surgery.

Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host an investor and analyst event on Monday, December 12, 2022 at 7:30 a.m. CST.

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) today announced new real-world data from the BECOME (BEhavior, COgnition, and More with Epidiolex ®) Caregiver Survey that showed a substantial proportion of caregivers of adult and pediatric patients with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS) prescribed Epidiolex.

Agilent Technologies Inc. (NYSE: A) today announced the opening of a new Customer Experience Center (CEC) in Lexington, MA, focused on solutions from Agilent genomics and diagnostics product portfolios.

Omnicell, Inc. today announced that it will showcase the Company’s Advanced Services at this year’s American Society of Health-System Pharmacists (ASHP) Midyear 2022 Clinical Meeting and Exhibition, to be held December 5-8, 2022 in Las Vegas.

Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced the publication of an article titled “Estimation of ENPP1 Deficiency Genetic Prevalence Using a Comprehensive Literature Review and Population Databases” in the Orphanet Journal of Rare Diseases.

Corvus Pharmaceuticals, Inc. announced that it will host an investor conference call to provide an update on CPI-818 data that will be presented at the 64th American Society of Hematology Annual Meeting and Exposition, along with an update on the Company’s development programs.